Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$0.02.

  • Fennec Pharmaceuticals' EPS (Basic) rose 9047.62% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.25, marking a year-over-year decrease of 52500.0%. This contributed to the annual value of -$0.02 for FY2024, which is 9733.76% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.02 for Q3 2025, which was up 9047.62% from -$0.11 recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' EPS (Basic) peaked at $0.47 during Q1 2024, and registered a low of -$0.4 during Q4 2022.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.16 (2021), whereas its average is -$0.13.
  • The largest annual percentage gain for Fennec Pharmaceuticals' EPS (Basic) in the last 5 years was 30434.78% (2024), contrasted with its biggest fall of 20000.0% (2024).
  • Over the past 5 years, Fennec Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.16 in 2021, then plummeted by 150.0% to -$0.4 in 2022, then soared by 75.0% to -$0.1 in 2023, then skyrocketed by 45.01% to -$0.05 in 2024, then soared by 63.63% to -$0.02 in 2025.
  • Its last three reported values are -$0.02 in Q3 2025, -$0.11 for Q2 2025, and -$0.04 during Q1 2025.